Skip to content

Effects of Adjunct Antimicrobial Photodynamic Therapy in Periodontal Treatment of Patients with Obesity

Effects of Antimicrobial Photodynamic Therapy in Non-surgical Periodontal Treatment of Patients with Obesity

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06073704
Enrollment
24
Registered
2023-10-10
Start date
2023-10-09
Completion date
2025-06-30
Last updated
2024-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis, Obesity

Keywords

periodontitis, obesity

Brief summary

The goal of this clinical trial is to compare the effects of adjuvant antimicrobial photodynamic therapy (aPDT) as an adjuvant of scaling and root planing with scaling and root planing alone for periodontal treatment in patients with periodontal disease and obesity. The main question it aims to answer are: Does adjuvant aPDT improves periodontal health? Are there differences in the proteomic profile of gingival fluid after both treatments? Participants will receive scaling and root planing complemented or not by aPDT. Results will be collected after 1, 3, and 6 months. Researchers will compare adjuvant aPDT treatment to regular treatment to see if it promotes reduction in inflammation and improvement in periodontal health.

Interventions

Scaling and root planing followed by antimicrobial photodynamic therapy

PROCEDUREControl

Treatment of scaling and root planing

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participants will be masked using a sham laser. Outcomes assessor will be blinded in relation to naming of the experimental groups.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Obesity (grade II and III classified according to Body Mass Index) * Periodontitis stage II to IV * Presence of at least 20 teeth excluding 3rd molars.

Exclusion criteria

* Smokers * Alcohol or drugs consumption * Kidney disorders * Pregnancy or lactation * Use of antibiotics at the last 30 days * Use of drugs that alter periodontal structures as phenytoin or ciclosporin * Periodontal treatment at the last 6 months

Design outcomes

Primary

MeasureTime frameDescription
Probing depthBaseline, 1, 3 and 6 monthsChanges in probing depth measured from the gingival margin to the bottom of periodontal sulcus or periodontal pocket by a periodontal probe in millimeters.
Clinical attachment levelBaseline, 1, 3 and 6 monthsChanges in clinical attachment level measured from the cemento-enamel junction to the bottom of periodontal sulcus or periodontal pocket by a periodontal probe in millimeters.

Secondary

MeasureTime frameDescription
Changes on bleeding on probingBaseline, 1,3,and 6 monthsChanges in percentage of sites with bleeding after probing. Six sites per tooth are examined and presence/absence of bleeding is recorded.
Differences in proteomicsbaseline, 3 and 6 monthsChanges in inflammatory proteins after treatment by proteomics assay. Presence or absence of proteins in gingival fluid are compared before and after treatment.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026